Frequent hemodialysis · Cardiac biomarkers · Klotho · Markers of collagen turnover · Left ventricular hypertrophy · Copeptin · Brain natriuretic peptide Abstract Background: Regression of left ventricular hypertrophy (LVH) is feasible with more frequent hemodialysis (HD). We aimed to ascertain pathways associated with regression of left ventricular mass (LVM) in patients enrolled in the Frequent HD Network (FHN) trials. Methods: This was a post hoc observational cohort study. We hypothesized LVH regression with frequent HD was associated with a different cardiovascular biomarker profile. Regressors were defined as patients who achieved a reduction of more than 10% in LVM at 12 months. Progressors were defined as patients who had a minimum of 10% increase in LVM at 12 months. Results: Among 332 randomized patients, 243 had biomarker data available. Of these, 121 patients did not progress or regress, 77 were regressors, and 45 were progressors. Mean LVM change differed between regressors and progressors by -65.6 (-74.0 to -57.2) g, p < 0.001. Regressors had a median (interquartile range) increase in dialysis frequency (from 3.0 inversely with changes in klotho (r = -0.24, p = 0.014). Conclusions: Markers of collagen turnover and changes in klotho levels are potential novel pathways associated with regression of LVH in the dialysis population, which will require further prospective validation.
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Introduction
Left ventricular hypertrophy (LVH) is prevalent in end-stage renal disease (ESRD) and contributes to the high annual mortality rate seen in these patients (15-20%) . While conventional hemodialysis (HD) (3 times per week, 3-4 h per session) is the standard renal replacement therapy in North America, it does not correct abnormal left ventricular geometry [1] .
Recent studies have highlighted the salutary effects of increased frequency or duration of HD on left ventricular mass (LVM). Given that reduction of LVH is associated with decreased risk of cardiovascular events [2] , LVM is a logical surrogate outcome of interest. Three randomized controlled trials in the field of intensive HD have included LVM as a primary outcome [3] [4] [5] . Culleton et al. [3] assigned 52 prevalent patients to 5-6 times per week nocturnal HD or conventional HD. After 6 months, mean LVM was -15.3 g (95% CI -29.6 to -1.0 g; p = 0.01) lower in the nocturnal HD group compared to controls. Similarly, the Frequent HD Network (FHN) Daily and Nocturnal Trials demonstrated a fall in LVM with adjusted mean LVM differences of -13.1 g (95% CI -21.3 to -5.0; p = 0.002) and -10.9 g (95% CI -23.7 to 1.8, p = 0.09), respectively. Predictors of LVM response to intensive HD included LVH at baseline and reduction in pre-dialysis systolic blood pressure [6] . It is important to note that changes in blood pressure accounted for less than 50% of the variability attributable to the changes in LVM suggesting that other important pathways may play a role in the pathogenesis of LVH and its regression in ESRD.
This is a post hoc study using data from the FHN Trials. We aimed to explore potential pathways associated with LVH regression and hypothesized that patients who experienced LVH regression with frequent HD (short daily and/or nocturnal HD) would manifest different responses in a series of a priori selected cardiovascular biomarkers. Given that biomarkers are also influenced by baseline level of LVH, we have also examined the impact of LVH regression on biomarker changes amongst individuals with evidence of LVH at baseline.
Concise Methods

FHN Trials
The FHN Daily and Nocturnal Trials were multicenter, randomized, prospective trials of in-center daily HD and home nocturnal HD, respectively, sponsored by the National Institute of Health, National Institutes Diabetes Digestive and Kidney Diseases (NIDDK) and the Center for Medicare and Medical Services. The designs, inclusion, and exclusion criteria of both Daily and Nocturnal Trials have been described previously [7, 8] 
Dialysis Intervention
Patients in the conventional arm of both trials remained on their usual 3 times per week HD prescription subject to a prescribed equilibrated Kt/V urea >1.1, a standardized Kt/V urea of >2.0 and a treatment time ≥2.5 h/session. Patients randomized to the frequent arm (6 times per week HD) of the daily trial were targeted to an equilibrated Kt/Vn, where Vn = 3.271 × V 2/3 , of 0.9 provided that the length of the session was between 1.5 and 2.75 h. Patients randomized to the frequent arm of the nocturnal trial followed HD prescriptions subject to a standardized Kt/V urea of ≥4.0 and a treatment time of ≥6 h (72 of 87 patients in the nocturnal trial received therapy at home, rather than in-center).
Cardiac Magnetic Resonance Imaging
We measured LVM and biventricular volumes by Cardiac Magnetic Resonance Imaging (CMRI) in all randomized patients at baseline and at 12 months where feasible. All CMRI images were analyzed centrally in a blinded manner. CMRI was performed on 1.5-T MRI systems (minimum gradient performance: peak strength ≥12 mT/m, slew rate ≥40 mTm/s) with dedicated surface coils. Sites were required to use standardized protocols utilizing breath-held, retrospective ECG-gated steady-state free precession imaging in contiguous short-axis views (8-mm slice thickness, 2 mm gap) that were carefully prescribed from localizer long-axis images. Imaging parameters were adjusted on each specific CMRI scanner to provide 20-25 cardiac phases with an in-plane spatial resolution superior of ≤2 mm and a temporal resolution <50 ms. Using validated software (Argus, Siemens medical Solutions, Erlangen, Germany), we measured myocardial volume on end-diastolic frames by manual tracing of endocardial and epicardial contours. We excluded papillary muscles from the calculation of myocardial mass. Subsequently, this volume was multiplied by the specific density of the myocardium (1.05 g/cm 3 ) to obtain LVM [9] . Similarly, we traced biventricular endocardial contours in end diastole and end systole to derive end-diastolic and end-systolic volumes. We used the formula of DuBois and DuBois to index LVM to body surface area [10] . We calculated anthropometric volume using the Watson equation [11] .
Regression of LVM ("regressors") was defined as patients who achieved a reduction of more than 10% in LVM at 12 months. "Progressors" was defined as patients who had a minimum of 10% increase in LVM at 12 months. A 10% cutoff was used to define regression as London et al. [12] had previously demonstrated favorable outcomes with a 10% LVM decrease in DOI: 10.1159/000488003 HD patients. LVH was defined as LVM index (LVM/body surface area) >84.1 g/m 2 (male) or >76.4 g/m 2 (female) according to Patel et al. [13] .
Cardiac Biomarkers Measurements
A priori, our consortium defined a select group of serum cardiac biomarkers that have been shown to be associated with various pathogenetic pathways leading to LVH development including the following: (1) brain natriuretic peptide (extracellular volume overload and ventricular stretch) (Millipore, St. Charles, MO, USA), with minimum detectability 11.5 pg/mL, intra-assay coefficient of variation (CV) 8.3%, and inter-assay CV 8.4%; (2) copeptin (EISA Phoenix Pharmaceuticals Inc., Burlingame CA, USA), with intraassay CV <10% and inter-assay CV <15% (neurohormonal activation); (3) matrix metalloproteinases (MMP) using a metallic bead kit enzyme-linked immunoassay (Millipore, St. Charles, MO, USA), with MMP-2 inter-assay CV 18% and intra-assay CV 5.4%, MMP-7 inter-assay CV 7.1% and intra-assay CV 3.7%, MMP-9 inter-assay CV 9.0% and intra-assay CV 1.9%; (4) tissue inhibitors of metalloproteinases (TIMP, Matrix remodeling and collagen deposition); (5) highly sensitive C reactive protein (inflammation) using a Polychem nephelometric assay (Polymedco, Cortland Manor, NY, USA), with assay range 0.08-160 mg/L, intra-assay CV 2.73-5.17, and inter-assay CV 4.67-5.67; (5) fibroblast growth factor 23 (FGF23) using a sandwich ELISA assay (Millipore, St. Charles, MO, USA) with inter-assay CV 2.45-11.31% and intra-assay CV 7.8-11.2%; and (6) Klotho (Immuno-Biological Laboratories Co., Ltd., Japan, with intra-assay CV 2.7-3.5% and inter-assay CV 2.9-11.4%) which has been shown to be a marker of myocardial fibrosis and LVH development in uremic animal models). In order to minimize variability between assays, all assays for time paired samples were carried out in duplicate on the same plate.
Data Analysis and Outcome Measures
Descriptive statistics for continuous variables were summarized using mean ± SD or median (interquartile range, IQR). Categorical variables were summarized using proportions. We compared groups by LVM response status using standard statistical methods, including Students t test for continuous variables and chi-squared or Fisher's exact test for categorical variables. The effects of LVM response on changes of biomarkers were estimated by applying a mixed effects model to baseline and 12-month values using an unstructured covariance matrix. We examined the association between changes in LVM and changes in cardiac biomarkers using Pearson correlations. In order to ascertain the effect of baseline LVH on biomarker evolution, the participants were further sub-classified according to LVH status. All analyses were conducted using SAS statistical software version 9.2 (Cary, NC, USA) and a p value criterion of <0.05 was chosen as the threshold for statistical significance.
Results
Among the 332 patients randomized across both trials (245 Daily, 87 Nocturnal), of whom 243 patients had LVM measurements as well as adequate serum samples for cardiac biomarker analyses. Of these, there were 77 patients classified as regressors (Daily: n = 25, 3×/week and n = 36, 6×/week; Nocturnal: n = 6, 3×/week and n = 10, 6×/week) and 45 patients classified as progressors (Daily: n = 18, 3×/week and n = 11, 6×/week; Nocturnal: n = 10, 3×/week, n = 6, 6×/week), with the remaining 121 patients not fulfilling either inclusion criteria. Selected baseline and clinical variables are shown in Table 1a and b. Mean LVM change differed between regressors and progressors by -65.60 (95% CI -74.04 to -57.15) g, p < 0.001. Specifically, LVM increased in the progressor group from 120 ± 41.5 to 151 ± 55.7 g and decreased in the regressor group from 158 ± 56.6 to 123 ± 43.9 g. At the end of follow-up, LV ejection fraction increased by 2.98 ± 10.6% in regressors and fell by -1.9 ± 9.30% in progressors, p = 0.01. Of note, patients who had LVM regression had higher ESRD vintage (p = 0.009) and tended to have a higher proportion with congestive heart failure (p = 0.045). There were no differences in the biomarker levels at baseline when comparing regressors and progressors (Table 1a) Table 2 ). Table 3 summarizes the differences in 12 month changes in all the priori defined biomarkers between progressors and regressors. Amongst the various cardiac biomarkers of interest, klotho levels increased significantly in patients with LVM regression versus those who had LVM progression. FGF23 fell in both groups and did not differ between regressors and progressors. This was accompanied by a significant decrease in phosphorus in both groups. Similarly, TIMP-1 and TIMP-2 levels fell and log (brain natriuretic peptide [BNP]) levels tended to fall in patients who had LVM regression in comparison to LVM progression. Aldosterone levels increased among regressors and decreased in progressors. After adjustment for changes of potassium and blood pressure, the difference in (log) aldosterone change between regressors and progressors (10.8, 95% CI -20.6 to 54.7) was not significant (p = 0.54). Of note (Fig. 1, 2) , changes in LVM correlated inversely with changes in klotho (r = -0.24, p = 0.014) and changes in logBNP were associated with changes in LVM (r = 0.32, p = 0.013). Similarly, changes in pre-systolic and diastolic blood pressures correlated with changes in LVM (r = 0.52, p < 0.001; r = 0.47, p < 0.001, respectively).
Amongst those patients with either LVH progression or regression, 34 patients had LVH at baseline and 88 pa- tients did not meet LVH criteria. Their demographics and biomarker results are described in Table 4 . The proportion of patients with baseline LVH which regressed had higher ESRD vintage (81%) than those who progressed (43%). Among those with LVH at baseline, copeptin increased from baseline to 12 months in progressors and declined in regressors with a difference of -87.2 ng/mL (95% CI -178.8 to 4.7, p = 0.06).
Discussion
LVH is an important risk factor for cardiovascular morbidity and mortality in patients with ESRD. Our group has previously documented the effect size of LVM reduction with the use of frequent HD. We have also reported the association between changes in blood pressure and reduction in LVM. While hemodynamics alteration Variables progress (n = 7) regress (n = 27) p value progress (n = 38) regress (n = 50) p value n n (%) or mean ± SD n n (%) or mean ± SD n n (%) or mean ± SD n n (%) or mean ± SD There is an emerging body of work that suggests pathological turnover of collagen is associated with LVH in the general population. Simplistically, excessive deposition of collagen may be controlled by overproduction of matrix, reduced removal or degradation of collagen, or both. Indeed, biomarkers reflecting changes in extracellular matrix fibrillary collagen homeostasis was predictive of LVH and diastolic dysfunction in a cross sectional analysis in 144 patients without ESRD [14] . Further, the matrix metalloproteinases/tissue inhibitors of metalloproteinases ratio were investigated in 103 general patients with hypertension and LVH. MMP/TIMP balance was suggested to play a role in predicting LV structure in the setting of hypertensive cardiac disease [15] . Additionally, a high level of TIMP was predictive of LVH and congestive heart failure in animal models and humans with hypertension [15] . The present observation suggests that MMP/TIMP balance is modifiable with the use of frequent HD. Specifically, regression in LVM was associated with a reduction in TIMP-2 levels resulting in a favorable MMP/TIMP ratio favoring extracellular matrix degradation. Whether the hypotensive effect of frequent HD or enhancement of solute or volume removal may affect MMP/TIMP in patients with ESRD is unknown. It is important to note that BNP tended to fall with LVH regression and correlated with changes in LVM. It is tempting to speculate that minimization of extracellular volume excess will lead to reduction in ventricular stretch, which is known to induce pathological extracellular matrix deposition [16, 17] . Our present data are consistent with the hypothesis that LVH regression in ESRD is dependent not only on changes in blood pressure alone; normalization of the MMP/TIMP may be a novel therapeutic target in patients with CKD and LVH.
Klotho is an anti-aging protein [18] which beneficially regulates various cellular processes, such as senescence, inflammation, apoptosis, fibrosis, and calcium and phosphate metabolism [19] . Uremic solutes retention is associated with reduction in Klotho levels [20] . In 86 patients with chronic kidney disease, LVH was inversely associated with klotho levels. In normal mice, intraperitoneal injection of indoxyl sulfate induced LVH was also accompanied by downregulation of klotho. In vitro, klotho inhibited cardiomyocyte hypertrophy by inhibiting p38 and extracellular signal regulated protein kinase 1/2 signaling pathways [21] . Restoration of klotho is feasible through an enhancement of peroxisome proliferation-activated receptor gamma acetylation [22] and is decreased through promoter hypermethylation [23] . Indeed, super-TAG methylation has been demonstrated to be associated with uremia-induced epigenetic dysregulation of atherosclerosis-related genes [24] . The present observation extends the existing literature by describing the potential therapeutic impact of frequent HD on the augmentation of klotho levels in patients with ESRD and LVH. It is tempting to speculate that frequent HD may modify epigenetic regulation of various genes [25] , which may result in an augmentation of klotho levels.
It is intriguing to note that LVH regression with frequent HD may occur in the setting of elevated levels of FGF23 [26] . Given that FGF23 has been suggested to induce LVH in in vitro and in vivo models [27] , the independent therapeutic effect of klotho on the heart requires additional prospective investigations. In our study, FGF23 levels declined in both progressors and regressors. FGF23 levels also declined significantly in all treatment groups, suggesting improvement in phosphate balance throughout the enrolled population. It is therefore unclear whether reduction in FGF23 may have played a permissive role among the population that responded to increased dialysis intensity.
It is interesting to note that there was a significant interaction between copeptin and LVH. Previously, our group has described a more pronounced reduction of LVM by frequent HD in patients with minimal residual renal function [28] . Using an observational study design, the MONDO investigators have also substantiated an independent association between pre-dialysis serum sodium and blood pressure variations [29] . Copeptin is part of the 164 amino acid precursor protein preprovasopressin together with vasopressin and neurophysin II. Recently, there is an emerging body of literature implicating the association between copeptin and cardiovascular mortality in patients with chronic kidney disease or ESRD [30] . Taken together, it is unclear whether copeptin may provide additional insights into the volume regulation of patients with ESRD and its cardiac sequelae.
Although our study represents the largest cohort of ESRD patients undergoing frequent HD with cardiac MRI and biomarker analyses, it is important to acknowledge the exploratory nature of the present work. Our DOI: 10.1159/000488003 sample size is limited to discern all potential pathways associated with LVH regression. In the future, additional biomarkers may be tested to enhance our present understanding of the biomarker profile of our patients with ESRD and LVH. We have also made multiple comparisons to explore potential mechanistic pathways. We also acknowledge that the present associative results cannot address causality but rather provide a novel trajectory of investigation. LVH is an important surrogate marker in ESRD. Using the Toronto nocturnal HD cohort, survival was demonstrated to be superior in patients with LVH regression [31] . We have illustrated 2 potentially important pathways contributing to LVM reduction in ESRD. Given the clinical impact of LVH regression in ESRD and the novel therapeutic potential of klotho and extracellular matrix homeostasis, our results may provide new therapeutic and dialysis targets for patients with ESRD.
